{"id":22580,"date":"2023-05-04T17:34:30","date_gmt":"2023-05-04T12:04:30","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=22580"},"modified":"2023-05-04T17:34:32","modified_gmt":"2023-05-04T12:04:32","slug":"medtech-news-for-apyx-medtronic-vivasure-sunmed","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-apyx-medtronic-vivasure-sunmed","title":{"rendered":"Apyx Medical Received FDA 510(k) Clearance for the Use of Renuvion; Medtronic\u2019s Next-generation Micra Leadless Pacing Systems; Concept Medical\u2019s MagicTouch Sirolimus Coated Balloon Catheter; Vivasure\u2019s Pivotal PATCH Study; SunMed Acquires the Vyaire\u2019s Respiratory &amp; Anesthesia Consumables Business; Eitan Medical\u2019s Connected Avoset&#x2122; Infusion Platform"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a1cc60a37ed3\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a1cc60a37ed3\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-apyx-medtronic-vivasure-sunmed\/#Apyx_Medical_Corporation_Received_FDA_510k_Clearance_for_the_Use_of_Renuvion%C2%AE_for_Coagulation_of_Subcutaneous_Soft_Tissues_Following_Liposuction_for_Aesthetic_Body_Contouring\" >Apyx Medical Corporation Received FDA 510(k) Clearance for the Use of Renuvion\u00ae for Coagulation of Subcutaneous Soft Tissues Following Liposuction for Aesthetic Body Contouring<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-apyx-medtronic-vivasure-sunmed\/#Concept_Medical_Received_IDE_Approval_to_Investigate_the_Safety_and_Efficacy_of_its_MagicTouch_Sirolimus_Coated_Balloon_Catheter_for_the_Treatment_Of_Small_Coronary_Artery_Disease\" >Concept Medical Received IDE Approval to Investigate the Safety and Efficacy of its MagicTouch Sirolimus Coated Balloon Catheter for the Treatment Of Small Coronary Artery Disease<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-apyx-medtronic-vivasure-sunmed\/#Eitan_Medical_Launched_the_Connected_Avoset%E2%84%A2_Infusion_Platform\" >Eitan Medical Launched the Connected Avoset&#x2122; Infusion Platform<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-apyx-medtronic-vivasure-sunmed\/#Medtronic_Received_FDA_Approval_for_its_Next-generation_Micra_Leadless_Pacing_Systems\" >Medtronic Received FDA Approval for its Next-generation Micra Leadless Pacing Systems<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-apyx-medtronic-vivasure-sunmed\/#Vivasure_Medical_Announced_Enrolment_of_First_Patient_in_Pivotal_PATCH_Study\" >Vivasure Medical Announced Enrolment of First Patient in Pivotal PATCH Study<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-apyx-medtronic-vivasure-sunmed\/#SunMed_Completed_the_Acquisition_of_the_Respiratory_Anesthesia_Consumables_Business_of_Vyaire_Medical\" >SunMed Completed the Acquisition of the Respiratory &amp; Anesthesia Consumables Business of Vyaire Medical<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-apyx-medical-corporation-received-fda-510-k-clearance-for-the-use-of-renuvion-for-coagulation-of-subcutaneous-soft-tissues-following-liposuction-for-aesthetic-body-contouring\"><span class=\"ez-toc-section\" id=\"Apyx_Medical_Corporation_Received_FDA_510k_Clearance_for_the_Use_of_Renuvion%C2%AE_for_Coagulation_of_Subcutaneous_Soft_Tissues_Following_Liposuction_for_Aesthetic_Body_Contouring\"><\/span><strong>Apyx Medical Corporation Received FDA 510(k) Clearance for the Use of Renuvion\u00ae for Coagulation of Subcutaneous Soft Tissues Following Liposuction for Aesthetic Body Contouring<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> April 28, 2023, <\/strong>Apyx Medical Corporation, the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion\u00ae, received 510(k) US Food and Drug Administration clearance for the utilization of the Renuvion APR Handpiece for the coagulation of subcutaneous soft tissues following <a href=\"https:\/\/www.delveinsight.com\/blog\/body-contouring-devices-market-outlook-and-key-trends\"><strong>liposuction for aesthetic body contouring<\/strong><\/a> purposes.&nbsp;<\/p>\n\n\n\n<p>With this, the Renuvion APR handpiece became the only device to have a 510(k) clearance for use following liposuction.&nbsp;<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&nbsp;<\/em>Charlie Goodwin, President, and Chief Executive Officer, of Apyx Medical Corporation, said<em>, \u201cWe are pleased to receive 510(k) clearance for the use of the Renuvion APR Handpiece for coagulation of subcutaneous soft tissues specifically following liposuction for aesthetic body contouring. The Renuvion APR handpiece is the only device to have a 510(k) clearance for use following liposuction.\u201d <\/em>Goodwin added,<em> \u201cThis 510(k) clearance further demonstrates the safety and effectiveness of our Renuvion technology and our continued commitment to working with the FDA to secure specific clinical indications.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>As per DelveInsight\u2019s <strong>\u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/body-contouring-devices-market\"><strong>Body Contouring Devices Market<\/strong><\/a><strong>\u201d <\/strong>report, the global body contouring devices market was valued at <strong>USD 1.40 billion<\/strong> in 2021, growing at a CAGR of <strong>7.34% <\/strong>during the forecast period from 2022 to 2027 to reach <strong>USD 2.25 billion<\/strong> by 2027. The increase in demand for body contouring devices is primarily attributed to the rising prevalence of obesity worldwide due to unhealthy lifestyles, which will increase the demand for the devices in the market.&nbsp;<\/p>\n\n\n\n<p>Additionally, a rise in awareness regarding non-invasive and minimally invasive body contouring procedures, a surge in aesthetic consciousness and its demand, and improved safety and efficacy of these techniques across the world are anticipated to bolster the market, thereby contributing to the growth of the body contouring devices market during the forecast period from 2022-2027. As per the <strong>Delveinsight <\/strong>analysis, in the product type segment of the body contouring devices market, the non-invasive segment is estimated to hold a significant share of the body contouring devices market in the year 2021. This can be ascribed to the various advantages that are associated with the segment. Non-invasive body contouring devices are safe, cost-effective, and give less pain experience to the patients as the procedures require zero cuts on the skin.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-concept-medical-received-ide-approval-to-investigate-the-safety-and-efficacy-of-its-magictouch-sirolimus-coated-balloon-catheter-for-the-treatment-of-small-coronary-artery-disease\"><span class=\"ez-toc-section\" id=\"Concept_Medical_Received_IDE_Approval_to_Investigate_the_Safety_and_Efficacy_of_its_MagicTouch_Sirolimus_Coated_Balloon_Catheter_for_the_Treatment_Of_Small_Coronary_Artery_Disease\"><\/span><strong>Concept Medical Received IDE Approval to Investigate the Safety and Efficacy of its MagicTouch Sirolimus Coated Balloon Catheter for the Treatment Of Small Coronary Artery Disease<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> April 25, 2023<\/strong>, Concept Medical Inc., was granted investigational device exemption (IDE) approval by US FDA for its novel MagicTouch Sirolimus Coated Balloon (SCB) which is intended for the treatment of Small Vessels (SV) in coronary arteries.&nbsp;<\/p>\n\n\n\n<p>The MagicTouch SCB is the first Sirolimus-coated balloon in the world, and it is widely used in commerce in Europe, key Asian markets, and Middle Eastern markets. In these markets, MagicTouch SCB has treated more than 100,000 patients.<\/p>\n\n\n\n<p>Small Vessel Disease is commonly witnessed in patients undergoing percutaneous coronary intervention (PCI) procedures and also remains an independent predictor of major adverse cardiac events (MACE).<\/p>\n\n\n\n<p>In addition to this most recent IDE approval for the treatment of small vessel indication, Concept Medical also received two other IDE approvals for the MagicTouch SCB family of products for the treatment of below-the-knee indication (PTA) and coronary in-stent restenosis (ISR) indication.<\/p>\n\n\n\n<p>With IDE approval, Concept Medical intends to initiate the pivotal clinical study to support the safety and effectiveness of the MagicTouch SCB in small vessel coronary disease. The data generated from this IDE clinical study will support a future pre-market approval (PMA) application in the USA.<\/p>\n\n\n\n<p>FDA-approved drug-coated balloons for the treatment of CAD are currently unavailable in the USA. Only uncoated balloons and Drug Eluting Stents are available to doctors. The EASTBOURNE Registry (2123 patients), NANOLUTE, and current trials like the TRANSFORM 1, TRANSFORM 2, GINGER, TITAN, and Hybrid Bifurcation DEB have all extensively researched MagicTouch SCB on a global scale. The therapy of coronary artery disease with sirolimus has already been shown to be safer.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>The FDA-approval to initiate the MAGICAL-SV Clinical trial using the MagicTouch sirolimus-covered balloon with novel coating technology represents a landmark event in our decades-long quest to find an optimal therapy to manage patients with small vessel coronary obstructive disease. Our US clinical investigators are thrilled and anxious to begin enrolment in close collaboration with the Cardiovascular Research Foundation and Concept Medical<\/em><\/p>\n<cite><strong>Dr. Martin Leon, MD (Founder and Chairman Emeritus, Cardiovascular Research Foundation), who will lead the coming IDE Trials<\/strong><\/cite><\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/balloon-catheters-market\"><strong>Balloon Catheters<\/strong><strong> <\/strong><strong>Market<\/strong><\/a>\u201d report, the global balloon catheters market was valued at <strong>USD 4.60 billion<\/strong> in 2021, growing at a CAGR of <strong>8.78%<\/strong> during the forecast period from 2022 to 2027 to reach <strong>USD 7.62 billion<\/strong> by 2027. Factors such as the rising prevalence of lifestyle disorders such as hypertension and obesity which present themselves as major risk factors for the <a href=\"https:\/\/www.delveinsight.com\/blog\/cardiovascular-disease-landscape\"><strong>development of cardiovascular diseases<\/strong><\/a> as well as brain aneurysms, increasing incidence of cancers in the pelvic region affecting the urinary system in varying capacities, growing geriatric population base where age itself plays a major role in disease etiology and technical innovation in product development such as the manufacture of drug-coated balloon catheters aimed at drug delivery at the site of action among other factors are expected to drive the balloon catheters market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-eitan-medical-launched-the-connected-avoset-infusion-platform\"><span class=\"ez-toc-section\" id=\"Eitan_Medical_Launched_the_Connected_Avoset%E2%84%A2_Infusion_Platform\"><\/span><strong>Eitan Medical Launched the Connected Avoset&#x2122; Infusion Platform<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> April 27, 2023<\/strong>, Eitan Medical, a global leader in advanced infusion therapy and drug delivery solutions with reliable innovations that put patients at the center of care, announced the launch of its new cutting-edge connected infusion multi-therapy ambulatory infusion system Avoset&#x2122;.<\/p>\n\n\n\n<p>With compact and simplified technology that can monitor infusion treatment data remotely, the connected Avoset&#x2122; Infusion System is designed to transform post-acute care and aims to enhance patient safety and improve the user experience.<\/p>\n\n\n\n<p>The Sapphire Infusion portfolio is completed by the Avoset<sup>TM<\/sup> Infusion Platform, which is particularly well suited to satisfy infusion requirements for therapies that demand safe pharmaceutical reservoirs and long battery life at modest flow rates. The MDR-certified Avoset Infusion Pump is now offered in a few European nations. In 2023, Eitan Medical anticipates launching Avoset on a global scale.<em>&nbsp;<\/em><\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>The recent spinout of Eitan Medical&#8217;s Sorrel wearable injection device business, allows Eitan Medical to focus on its core connected infusion system solutions. The launch of Avoset will transform infusion therapy in alternate sites and is not only a triumph of innovation and technology but also a testament to the dedication of Eitan Medical to providing the best possible care for patients. It is a moment of excitement and hope, as we look forward to the transformative impact these solutions will have on the lives of many patients and caregivers around the world<\/em>.<\/p>\n<cite><strong>Shaul Eitan, GM and President of Eitan Medical, Medication Delivery Solutions<\/strong><\/cite><\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>We are thrilled to launch the Avoset Infusion Platform, an innovative connected ambulatory infusion pump that will transform the way patients receive treatment in post-acute care. We are confident that this new infusion pump will make a positive impact on the lives of patients and their caregivers, providing them with the freedom and flexibility to manage their treatment from the comfort of their own homes. This confirms that Eitan Medical is set for sustainable growth with a focus on a strong innovation roadmap that will redefine the drug delivery market<\/em>.<\/p>\n<cite><strong>Roger Massengale, Chief Commercial Officer of Eitan Medical<\/strong><\/cite><\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/infusion-pumps-market\"><strong>Infusion Pumps Market<\/strong><\/a>\u201d report, the global infusion pumps market was valued at <strong>USD 13.80 billion<\/strong> in 2021, growing at a CAGR of <strong>9.54%<\/strong> during the forecast period from 2022 to 2027, to reach <strong>USD 23.85 billion<\/strong> by 2027. The demand for infusion pumps is primarily motivated by the increasing prevalence of chronic diseases, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/patient-monitoring-devices-market\"><strong>increase in the demand for remote patient monitoring<\/strong><\/a>, growing research and development activities to launch home infusion systems, and the increasing cost of hospital-based infusion therapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-medtronic-received-fda-approval-for-its-next-generation-micra-leadless-pacing-systems\"><span class=\"ez-toc-section\" id=\"Medtronic_Received_FDA_Approval_for_its_Next-generation_Micra_Leadless_Pacing_Systems\"><\/span><strong>Medtronic Received FDA Approval for its Next-generation Micra Leadless Pacing Systems<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On <strong>May 1, 2023,<\/strong> Medtronic plc, the global leader in medical technology, got the US Food and Drug Administration (FDA) approval for its Micra&#x2122; AV2 and Micra&#x2122; VR2, the next generation of its industry-leading miniaturized, leadless pacemakers.<\/p>\n\n\n\n<p>The tiniest pacemakers in the world, the Micra AV2, and Micra VR2, offer a longer battery life and simpler programming than previous Micra models while still providing the many advantages of leadless pacing, such as fewer problems compared to conventional pacemakers.<\/p>\n\n\n\n<p>The median expected battery life of the Micra AV2 and Micra VR2 is about 16 and 17 years, respectively, with over 40% greater battery life compared to earlier generations. According to projections, more than 80% of individuals who receive a Micra will only require one device for the rest of their lives.&nbsp;<\/p>\n\n\n\n<p>Advanced algorithms that automatically program AV synchronization and so synchronize the upper and lower chambers of the heart are also a feature of the new Micra AV2. Additionally, the Micra AV2 has a higher tracking capability for faster heart rates for active patients.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>Camille Frazier-Mills, M.D., MHS, an electrophysiologist at Duke University Health System, said<em> &#8220;Improved AV synchrony \u2013 requiring less in-office reprogramming thanks to algorithm optimization \u2013 and longer battery life are major wins for patients.&#8221; <\/em>Camille commented<em> I&#8217;m excited to offer my patients the new Micra devices. This best-in-class technology transforms the patient experience by eliminating pocket-related complications, and now reduces the chance that patients will need their device changed in the future.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/pacemakers-market\"><strong>Pacemakers Market<\/strong><\/a>\u201d report, the global pacemakers market was valued at <strong>USD 4.88 billion<\/strong> in 2021, growing at a CAGR of <strong>5.85%<\/strong> during the forecast period from 2022 to 2027, to reach <strong>USD 6.84 billion<\/strong> by 2027. The demand for pacemakers is primarily motivated due to the <a href=\"https:\/\/www.delveinsight.com\/blog\/upcoming-cardiovascular-drugs\"><strong>rise in cardiovascular diseases (CVDs)<\/strong><\/a>, superior treatment outcomes of sudden cardiac arrests, and growing technological advancements.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-vivasure-medical-announced-enrolment-of-first-patient-in-pivotal-patch-study\"><span class=\"ez-toc-section\" id=\"Vivasure_Medical_Announced_Enrolment_of_First_Patient_in_Pivotal_PATCH_Study\"><\/span><strong>Vivasure Medical Announced Enrolment of First Patient in Pivotal PATCH Study<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> May 2, 2023, <\/strong>Vivasure Medical, a company pioneering novel fully absorbable technology for percutaneous vessel closure, announced the enrolment of the first patient in the company\u2019s PerQseal\u00ae PATCH Clinical Study, at Kaleida Health&#8217;s Buffalo General Medical Center-Gates Vascular Institute in Buffalo, New York by Dr. Vijay Iyer, Chief of Cardiology at the University of Buffalo and Director, Structural Heart Interventions at Buffalo General Hospital.<\/p>\n\n\n\n<p>The PATCH clinical study is a multi-center, single-arm, pivotal study that aims to evaluate the safety and efficacy of the Vivasure PerQseal Closure Device System which is the first suture-less, fully absorbable synthetic implant for large-bore vessel punctures. PerQseal is placed from inside the vessel, which makes the deployment simpler and offers more control than conventional closure techniques.<\/p>\n\n\n\n<p>The trial expects to enroll up to 171 patients across the US and up to 90 patients in up to eight European investigational sites. The data will support a pre-market approval submission to the US Food and Drug Administration (FDA).<\/p>\n\n\n\n<p>PerQseal is meant for addressing the major vascular complications, such as vessel distortion at the closure site, which may lead to stenosis, thrombus formation, and abrupt closure among others because of the utilization of suture-or collagen-based closure devices for the closure of large hole arterial access made during percutaneous cardiovascular procedures, including transcatheter aortic valve replacement (TAVR), thoracic and abdominal endovascular aneurysm repair (TEVAR and EVAR), and the use of a cardiac assist device (CAD).<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWith the recent proliferation of large bore arterial access, there\u2019s a moment after each procedure when vessel management is critical and clinicians must quickly and effectively close it to reduce unnecessary, potentially life-threatening bleeding,\u201d<\/em> said Dr. William Gray, system chief in the division of cardiovascular disease at Main Line Health, co-director at the Lankenau Heart Institute in Philadelphia and the principal investigator for the PerQseal PATCH study. William added, <em>\u201cI look forward to evaluating the PerQseal technology and its simplified, controlled technique \u2013 with the ultimate goal of reducing vascular complications for these patients.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/vascular-patches-market\"><strong>Vascular Patches Market<\/strong><\/a>\u201d report, the global vascular market is estimated to grow at a CAGR of <strong>7.37%<\/strong> during the forecast period from 20232 to 2027. The increase in demand for vascular patches is primarily attributed to the increase in the prevalence of cardiovascular diseases due to genetic factors, <a href=\"https:\/\/www.delveinsight.com\/report-store\/ageing-pipeline-insight\"><strong>age<\/strong><\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/weight-loss-weight-management-obesity-market\"><strong>obesity<\/strong><\/a>, unhealthy and sedentary lifestyles, bad eating habits, and an increasing number of geriatric patients prone to vascular diseases, increasing use of vascular patches in surgeries, <a href=\"https:\/\/www.delveinsight.com\/report-store\/surgical-robotic-system-market\"><strong>increased demand of minimally invasive surgeries (MIS)<\/strong><\/a>, and technological advancements like vascular cell regeneration, cellular integration, and tissue remodeling across the world are anticipated to bolster the market, thereby contributing to the growth of the vascular patches market during the forecast period from 2022-2027.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-sunmed-completed-the-acquisition-of-the-respiratory-anesthesia-consumables-business-of-vyaire-medical\"><span class=\"ez-toc-section\" id=\"SunMed_Completed_the_Acquisition_of_the_Respiratory_Anesthesia_Consumables_Business_of_Vyaire_Medical\"><\/span><strong>SunMed Completed the Acquisition of the Respiratory &amp; Anesthesia Consumables Business of Vyaire Medical<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On <strong>May 1, 2023<\/strong>, SunMed, a leading North American manufacturer and distributor of consumable medical devices for anesthesia and respiratory care, completed the acquisition of Vyaire Medical\u2019s business unit that manufactures and markets respiratory and anesthesia consumables.&nbsp;<\/p>\n\n\n\n<p>By combining, SunMed will create a market leader wholly focused on airway management and surgical care with a more comprehensive offering for practitioners. This company will act as a one-stop shop for the best <a href=\"https:\/\/www.delveinsight.com\/report-store\/anesthetic-effect-market\"><strong>medical consumables for anesthesia<\/strong><\/a> and respiratory care, supporting the best patient outcomes. The acquisition&#8217;s terms weren&#8217;t made public.&nbsp;<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cWe are pleased to officially welcome Vyaire\u2019s respiratory and anesthesia consumables team into the SunMed family and are excited by the promising opportunities created by the joining of two great businesses. As we bring our people together, we are confident in the highly complementary nature of our platforms and in our ability to strengthen our manufacturing capabilities and ensure our customer&#8217;s reliable and predictable supply of the most trusted respiratory and anesthesia consumables. Together, we will be even better positioned to drive innovation, using our combined expertise and industry-leading engineering capabilities. Our mission will continue to be focused on improving quality of life and setting the standard of care.\u201d<\/p>\n<cite><strong>Hank Struik, CEO of SunMed<\/strong><\/cite><\/blockquote>\n\n\n\n<p>According to<strong> <\/strong>DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/anesthesia-workstation-machines-market\"><strong>Anaesthesia Machines Market<\/strong><\/a>\u201d report, the global anesthesia machines market is estimated to advance at a <strong>CAGR <\/strong>of<strong> 8.2%<\/strong> during the forecast period. The rise in demand for anesthesia machines is primarily attributed to the growing burden of various surgeries that requires the administration of anesthesia to the patient during the operation among the worldwide population, increasing chronic diseases, and amassed old age population.\u00a0<\/p>\n\n\n\n<p>In addition, an increase in investment and funds by the companies for the development of anesthesia machines are also the factors responsible for the global Anaesthesia Machines market growth during the forecast period. As per <strong>DelveInsigt\u2019s<\/strong> analysis, in the product type segment, the anesthesia delivery machines that not only allow procedures to be performed without pain to the patient but also ensure patient safety throughout, allowing surgeons to achieve the best possible results are expected to hold the major share in the global anesthesia machines market.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Apyx Medical Corporation Received FDA 510(k) Clearance for the Use of Renuvion\u00ae for Coagulation of Subcutaneous Soft Tissues Following Liposuction for Aesthetic Body Contouring On April 28, 2023, Apyx Medical Corporation, the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion\u00ae, received 510(k) US Food and Drug Administration clearance for [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":22582,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":9,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[19897,20648,20640,19053,19842,20599,20600,20641,187,20642,17022,19709,2753,17020,17021,16779,16975,18799,16968,420,17037,19085,20646,20645,20644,20643,20647],"industry":[17226],"therapeutic_areas":[17242,17237],"class_list":["post-22580","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-anaesthesia-machines","tag-anaesthesia-machines-market","tag-apyx-medical","tag-balloon-catheters","tag-balloon-catheters-market","tag-body-contouring-devices","tag-body-contouring-devices-market","tag-concept-medical","tag-coronary-artery-disease","tag-eitan-medical","tag-infusion-pumps","tag-infusion-pumps-market","tag-medical-device","tag-medical-devices","tag-medical-devices-market","tag-medtech","tag-medtech-market","tag-medtech-news","tag-medtronic","tag-news","tag-pacemakers","tag-pacemakers-market","tag-sunmed","tag-vascular-patches","tag-vascular-patches-market","tag-vivasure-medical","tag-vyaire-medical","industry-medical-devices","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-dermatology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MedTech News | Apyx, Medtronic, Vivasure, SunMed, Eitan<\/title>\n<meta name=\"description\" content=\"Apyx&#039;s Renuvion; Eitan&#039;s Avoset\u2122 Infusion Platform; Vivasure\u2019s PATCH Study; Medtronic\u2019s Micra Leadless Pacing Systems; SunMed, Concept Medical\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-apyx-medtronic-vivasure-sunmed\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedTech News | Apyx, Medtronic, Vivasure, SunMed, Eitan\" \/>\n<meta property=\"og:description\" content=\"Apyx&#039;s Renuvion; Eitan&#039;s Avoset\u2122 Infusion Platform; Vivasure\u2019s PATCH Study; Medtronic\u2019s Micra Leadless Pacing Systems; SunMed, Concept Medical\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-apyx-medtronic-vivasure-sunmed\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-04T12:04:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-04T12:04:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/04172721\/MedTech-News-and-Updates-for-Apyx-Medtronic-Vivasure-SunMed-Eitan-Medical-Concept-Medical-Vyaire-Medical.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MedTech News | Apyx, Medtronic, Vivasure, SunMed, Eitan","description":"Apyx's Renuvion; Eitan's Avoset\u2122 Infusion Platform; Vivasure\u2019s PATCH Study; Medtronic\u2019s Micra Leadless Pacing Systems; SunMed, Concept Medical","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-apyx-medtronic-vivasure-sunmed","og_locale":"en_US","og_type":"article","og_title":"MedTech News | Apyx, Medtronic, Vivasure, SunMed, Eitan","og_description":"Apyx's Renuvion; Eitan's Avoset\u2122 Infusion Platform; Vivasure\u2019s PATCH Study; Medtronic\u2019s Micra Leadless Pacing Systems; SunMed, Concept Medical","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-apyx-medtronic-vivasure-sunmed","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-05-04T12:04:30+00:00","article_modified_time":"2023-05-04T12:04:32+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/04172721\/MedTech-News-and-Updates-for-Apyx-Medtronic-Vivasure-SunMed-Eitan-Medical-Concept-Medical-Vyaire-Medical.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-apyx-medtronic-vivasure-sunmed","url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-apyx-medtronic-vivasure-sunmed","name":"MedTech News | Apyx, Medtronic, Vivasure, SunMed, Eitan","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-apyx-medtronic-vivasure-sunmed#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-apyx-medtronic-vivasure-sunmed#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/04172721\/MedTech-News-and-Updates-for-Apyx-Medtronic-Vivasure-SunMed-Eitan-Medical-Concept-Medical-Vyaire-Medical.png","datePublished":"2023-05-04T12:04:30+00:00","dateModified":"2023-05-04T12:04:32+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Apyx's Renuvion; Eitan's Avoset\u2122 Infusion Platform; Vivasure\u2019s PATCH Study; Medtronic\u2019s Micra Leadless Pacing Systems; SunMed, Concept Medical","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-news-for-apyx-medtronic-vivasure-sunmed"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-apyx-medtronic-vivasure-sunmed#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/04172721\/MedTech-News-and-Updates-for-Apyx-Medtronic-Vivasure-SunMed-Eitan-Medical-Concept-Medical-Vyaire-Medical.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/04172721\/MedTech-News-and-Updates-for-Apyx-Medtronic-Vivasure-SunMed-Eitan-Medical-Concept-Medical-Vyaire-Medical.png","width":772,"height":482,"caption":"MedTech News and Updates for Apyx, Medtronic, Vivasure, SunMed, Eitan Medical, Concept Medical, Vyaire Medical"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/04172721\/MedTech-News-and-Updates-for-Apyx-Medtronic-Vivasure-SunMed-Eitan-Medical-Concept-Medical-Vyaire-Medical-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Anaesthesia Machines<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Anaesthesia Machines Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Apyx Medical<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Balloon Catheters<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Balloon Catheters Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Body Contouring Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Body Contouring Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Concept Medical<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Coronary artery disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Eitan Medical<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Infusion Pumps<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Infusion Pumps Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">medical device<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech News<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medtronic<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pacemakers<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pacemakers Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">SunMed<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Vascular Patches<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Vascular Patches Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Vivasure Medical<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Vyaire Medical<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Anaesthesia Machines<\/span>","<span class=\"advgb-post-tax-term\">Anaesthesia Machines Market<\/span>","<span class=\"advgb-post-tax-term\">Apyx Medical<\/span>","<span class=\"advgb-post-tax-term\">Balloon Catheters<\/span>","<span class=\"advgb-post-tax-term\">Balloon Catheters Market<\/span>","<span class=\"advgb-post-tax-term\">Body Contouring Devices<\/span>","<span class=\"advgb-post-tax-term\">Body Contouring Devices Market<\/span>","<span class=\"advgb-post-tax-term\">Concept Medical<\/span>","<span class=\"advgb-post-tax-term\">Coronary artery disease<\/span>","<span class=\"advgb-post-tax-term\">Eitan Medical<\/span>","<span class=\"advgb-post-tax-term\">Infusion Pumps<\/span>","<span class=\"advgb-post-tax-term\">Infusion Pumps Market<\/span>","<span class=\"advgb-post-tax-term\">medical device<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech<\/span>","<span class=\"advgb-post-tax-term\">MedTech Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech News<\/span>","<span class=\"advgb-post-tax-term\">Medtronic<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Pacemakers<\/span>","<span class=\"advgb-post-tax-term\">Pacemakers Market<\/span>","<span class=\"advgb-post-tax-term\">SunMed<\/span>","<span class=\"advgb-post-tax-term\">Vascular Patches<\/span>","<span class=\"advgb-post-tax-term\">Vascular Patches Market<\/span>","<span class=\"advgb-post-tax-term\">Vivasure Medical<\/span>","<span class=\"advgb-post-tax-term\">Vyaire Medical<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on May 4, 2023","modified":"Updated on May 4, 2023"},"absolute_dates_time":{"created":"Posted on May 4, 2023 5:34 pm","modified":"Updated on May 4, 2023 5:34 pm"},"featured_img_caption":"MedTech News and Updates for Apyx, Medtronic, Vivasure, SunMed, Eitan Medical, Concept Medical, Vyaire Medical","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/22580","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=22580"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/22580\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/22582"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=22580"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=22580"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=22580"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=22580"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=22580"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}